The following articles (labelled with PubMed ID or TBD) are for your review
| PMID | Data | Article Title | Organization |
|---|
| 28235701 |
10 |
Design, synthesis, and biological evaluation of imidazo[1,2-b]pyridazine derivatives as mTOR inhibitors. |
Peking University |
| 28017532 |
140 |
Discovery of triazole aminopyrazines as a highly potent and selective series of PI3Kd inhibitors. |
Astrazeneca |
| 26652969 |
15 |
Synthesis and antitumor activity evaluation of PI3K inhibitors containing 3-substituted quinazolin-4(3H)-one moiety. |
Xi'An Jiaotong University |
| 28109945 |
25 |
Discovery of a series of N-(5-(quinolin-6-yl)pyridin-3-yl)benzenesulfonamides as PI3K/mTOR dual inhibitors. |
Hangzhou Xixi Hospital |
| 28105286 |
65 |
Discovery of a Potent, Selective, and Orally Available PI3Kd Inhibitor for the Treatment of Inflammatory Diseases. |
RhôNe-Poulenc Rorer |
| 27479483 |
61 |
6-Aryl substituted 4-(4-cyanomethyl) phenylamino quinazolines as a new class of isoform-selective PI3K-alpha inhibitors. |
Csir-Indian Institute of Integrative Medicine |
| 27644332 |
59 |
Class II Phosphoinositide 3-Kinases as Novel Drug Targets. |
Curtin University |
| 27660692 |
70 |
Discovery of a Selective Phosphoinositide-3-Kinase (PI3K)-¿ Inhibitor (IPI-549) as an Immuno-Oncology Clinical Candidate. |
Infinity Pharmaceuticals |
| 27186676 |
186 |
Development of Purine-Based Hydroxamic Acid Derivatives: Potent Histone Deacetylase Inhibitors with Marked in Vitro and in Vivo Antitumor Activities. |
West China Hospital of Sichuan University |
| 27189888 |
11 |
Optimization of the phenylurea moiety in a phosphoinositide 3-kinase (PI3K) inhibitor to improve water solubility and the PK profile by introducing a solubilizing group and ortho substituents. |
Chugai Pharmaceutical |
| 26321603 |
8 |
Synthesis and anticancer effects evaluation of 1-alkyl-3-(6-(2-methoxy-3-sulfonylaminopyridin-5-yl)benzo[d]thiazol-2-yl)urea as anticancer agents with low toxicity. |
Xi'An Jiaotong University |
| 23644197 |
51 |
Synthesis and biological evaluation of novel phosphatidylinositol 3-kinase inhibitors: Solubilized 4-substituted benzimidazole analogs of 2-(difluoromethyl)-1-[4,6-di(4-morpholinyl)-1,3,5-triazin-2-yl]-1H-benzimidazole (ZSTK474). |
University of Auckland |
| 23291120 |
2 |
Synthesis and biological evaluation of novel coumarin-pyrazoline hybrids endowed with phenylsulfonyl moiety as antitumor agents. |
Cairo University |
| 22520259 |
65 |
Identification of ETP-46321, a potent and orally bioavailable PI3Ka,d inhibitor. |
Spanish National Cancer Research Centre (Cnio) |
| 22897589 |
100 |
Selective class I phosphoinositide 3-kinase inhibitors: optimization of a series of pyridyltriazines leading to the identification of a clinical candidate, AMG 511. |
Amgen |
| 23040731 |
4 |
Viridin analogs derived from steroidal building blocks. |
University of Connecticut |
| 23063566 |
70 |
Synthesis and biological evaluation of new 5-benzylated 4-oxo-3,4-dihydro-5H-pyridazino[4,5-b]indoles as PI3Ka inhibitors. |
Universit£ |
| 22325943 |
71 |
Imidazo[1,2-a]pyrazines as novel PI3K inhibitors. |
Spanish National Cancer Research Centre (Cnio) |
| 21621413 |
24 |
Discovery and optimization of potent and selective benzonaphthyridinone analogs as small molecule mTOR inhibitors with improved mouse microsome stability. |
Dana-Farber Cancer Institute |
| 21322566 |
61 |
Discovery of 9-(6-aminopyridin-3-yl)-1-(3-(trifluoromethyl)phenyl)benzo[h][1,6]naphthyridin-2(1H)-one (Torin2) as a potent, selective, and orally available mammalian target of rapamycin (mTOR) inhibitor for treatment of cancer. |
Dana-Farber Cancer Institute |
| 20860370 |
83 |
Discovery of 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo[h][1,6]naphthyridin-2(1H)-one as a highly potent, selective mammalian target of rapamycin (mTOR) inhibitor for the treatment of cancer. |
Dana-Farber Cancer Institute |
| 17562705 |
6 |
Inhibition of mammalian target of rapamycin signaling by 2-(morpholin-1-yl)pyrimido[2,1-alpha]isoquinolin-4-one. |
Stony Brook University |
| 16464575 |
7 |
Synthesis of fluorescent derivatives of wortmannin and demethoxyviridin as probes for phosphatidylinositol 3-kinase. |
State University of New York-Esf |
| 32317209 |
8 |
Design, synthesis and antiproliferative activity evaluation of a series of pyrrolo[2,1-f][1,2,4]triazine derivatives. |
Central South University |
| 32551006 |
134 |
Discovery of an Atropisomeric PI3K? Selective Inhibitor through Optimization of the Hinge Binding Motif. |
Gilead Sciences |
| 11206452 |
14 |
3-Deoxy-3-substituted-D-myo-inositol imidazolyl ether lipid phosphates and carbonate as inhibitors of the phosphatidylinositol 3-kinase pathway and cancer cell growth. |
Georgetown University Medical Center |
| 30850264 |
108 |
Synthesis and biological evaluation of solubilized sulfonamide analogues of the phosphatidylinositol 3-kinase inhibitor ZSTK474. |
University of Auckland |
| 31851518 |
61 |
The Discovery of 7-Methyl-2-[(7-methyl[1,2,4]triazolo[1,5- |
Astrazeneca |
| 30878826 |
45 |
Design, synthesis and biological evaluation of novel benzothiadiazine derivatives as potent PI3K?-selective inhibitors for treating B-cell-mediated malignancies. |
Zhejiang University |
| 31693351 |
473 |
Discovery of 4 |
TBA |
| 32069401 |
27 |
Design, Synthesis, and Biological Evaluation of Imidazo[1,2- |
East China Normal University |
| 31550151 |
17 |
The Exploration of Chirality for Improved Druggability within the Human Kinome. |
University of Arkansas For Medical Sciences |
| 31074988 |
95 |
Rational Design of 5-(4-(Isopropylsulfonyl)phenyl)-3-(3-(4-((methylamino)methyl)phenyl)isoxazol-5-yl)pyrazin-2-amine (VX-970, M6620): Optimization of Intra- and Intermolecular Polar Interactions of a New Ataxia Telangiectasia Mutated and Rad3-Related (ATR) Kinase Inhibitor. |
Vertex Pharmaceuticals (Europe) |
| 30986068 |
112 |
Structure Overhaul Affords a Potent Purine PI3K? Inhibitor with Improved Tolerability. |
TBA |
| 30418766 |
35 |
Kinase and Histone Deacetylase Hybrid Inhibitors for Cancer Therapy. |
Qingdao University |
| 30530193 |
64 |
Targeting the immunity protein kinases for immuno-oncology. |
China Pharmaceutical University |
| 30015489 |
16 |
Atropisomerism by Design: Discovery of a Selective and Stable Phosphoinositide 3-Kinase (PI3K) ? Inhibitor. |
Gilead Sciences |
| 31855425 |
224 |
Optimization of Orally Bioavailable PI3K? Inhibitors and Identification of Vps34 as a Key Selectivity Target. |
Glaxosmithkline |
| 31465220 |
139 |
A Conformational Restriction Strategy for the Identification of a Highly Selective Pyrimido-pyrrolo-oxazine mTOR Inhibitor. |
University of Basel |
| 31335136 |
29 |
Discovery of 4-Methylquinazoline Based PI3K Inhibitors for the Potential Treatment of Idiopathic Pulmonary Fibrosis. |
TBA |
| 28106991 |
136 |
Discovery of a Phosphoinositide 3-Kinase (PI3K) ?/? Inhibitor for the Treatment of Phosphatase and Tensin Homolog (PTEN) Deficient Tumors: Building PI3K? Potency in a PI3K?-Selective Template by Targeting Nonconserved Asp856. |
Gilead Sciences |
| 30071408 |
56 |
Difuran-substituted quinoxalines as a novel class of PI3K? H1047R mutant inhibitors: Synthesis, biological evaluation and structure-activity relationship. |
Chongqing University |
| 30237123 |
12 |
Piperidinyl-embeded chalcones possessing anti PI3K? inhibitory properties exhibit anti-atopic properties in preclinical models. |
Inserm 1052/Cnrs 5286/University of Lyon |
| 30077608 |
24 |
Design and synthesis of benzofuro[3,2-b]pyridin-2(1H)-one derivatives as anti-leukemia agents by inhibiting Btk and PI3K?. |
China Pharmaceutical University |
| 29631787 |
21 |
Discovery and biological evaluation of novel pyrazolopyridine derivatives as potent and orally available PI3K? inhibitors. |
Astellas Pharma |
| 29475582 |
8 |
Novel 4-aminoquinazoline derivatives induce growth inhibition, cell cycle arrest and apoptosis via PI3K? inhibition. |
Shenyang Pharmaceutical University |
| 30034607 |
60 |
Discovery of an Orally Bioavailable Dual PI3K/mTOR Inhibitor Based on Sulfonyl-Substituted Morpholinopyrimidines. |
Shanghai Haiyan Pharmaceutical Technology |
| 28835805 |
45 |
Discovery of a Novel Series of 7-Azaindole Scaffold Derivatives as PI3K Inhibitors with Potent Activity. |
Fudan University |
| 28800461 |
16 |
Design, synthesis, and biological evaluation of novel 3-substituted imidazo[1,2-a]pyridine and quinazolin-4(3H)-one derivatives as PI3K? inhibitors. |
Shenyang Pharmaceutical University |
| 29017786 |
35 |
Identification of novel PI3K inhibitors through a scaffold hopping strategy. |
Spanish National Cancer Research Centre (Cnio) |
| 28958845 |
147 |
Synthesis and biological evaluation of sulfonamide analogues of the phosphatidylinositol 3-kinase inhibitor ZSTK474. |
University of Auckland |
| 30351000 |
119 |
Discovery of a Novel Inhaled PI3K? Inhibitor for the Treatment of Respiratory Diseases. |
TBA |
| 28494256 |
11 |
Designing multi-targeted agents: An emerging anticancer drug discovery paradigm. |
Hunan University of Chinese Medicine |
| 29852070 |
101 |
Discovery of Highly Isoform Selective Orally Bioavailable Phosphoinositide 3-Kinase (PI3K)-? Inhibitors. |
Pharmaron-Beijing |
| 28835793 |
32 |
Structure-Guided Design and Initial Studies of a Bifunctional MEK/PI3K Inhibitor (ST-168). |
University of Michigan |
| 28409639 |
83 |
Design, Synthesis, and Biological Evaluation of Dimorpholine Substituted Thienopyrimidines as Potential Class I PI3K/mTOR Dual Inhibitors. |
West China Hospital of Sichuan University |
| 28571824 |
65 |
Design, synthesis and SAR of new-di-substituted pyridopyrimidines as ATP-competitive dual PI3K?/mTOR inhibitors. |
Temple University |
| 28829592 |
109 |
5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a Potent, Brain-Penetrant, Orally Bioavailable, Pan-Class I PI3K/mTOR Inhibitor as Clinical Candidate in Oncology. |
University of Basel |
| 28404374 |
81 |
Generation of tricyclic imidazo[1,2-a]pyrazines as novel PI3K inhibitors by application of a conformational restriction strategy. |
Spanish National Cancer Research Centre (Cnio) |
| 28520415 |
91 |
Design and Synthesis of Soluble and Cell-Permeable PI3K? Inhibitors for Long-Acting Inhaled Administration. |
Astrazeneca |
| 27082499 |
10 |
Discovery of a Highly Selective STK16 Kinase Inhibitor. |
Chinese Academy of Sciences |
| 19848404 |
44 |
Discovery of potent and selective inhibitors of the mammalian target of rapamycin (mTOR) kinase. |
Wyeth Research |
| 19645448 |
48 |
ATP-Competitive Inhibitors of the Mammalian Target of Rapamycin: Design and Synthesis of Highly Potent and Selective Pyrazolopyrimidines |
Wyeth Research |
| 17685602 |
33 |
Discovery of 3,3'-(2,4-diaminopteridine-6,7-diyl)diphenol as an isozyme-selective inhibitor of PI3K for the treatment of ischemia reperfusion injury associated with myocardial infarction. |
Targegen |
| 17172449 |
20 |
Phosphoinositide 3-kinase gamma/delta inhibition limits infarct size after myocardial ischemia/reperfusion injury. |
Targegen |
| 18754654 |
19 |
The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer . |
Piramed Pharma |
| 18269228 |
93 |
Synthesis and structure-activity relationships of ring-opened 17-hydroxywortmannins: potent phosphoinositide 3-kinase inhibitors with improved properties and anticancer efficacy. |
Wyeth Research |
| 11090628 |
5 |
Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine. |
Mrc |
Search and Browse
